X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): EB005
Therapeutic Area: Dermatology Product Name: EB005
Highest Development Status: Discovery Product Type: Undisclosed
Partner/Sponsor/Collaborator: GlaxoSmithKline
Deal Size: $224.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration January 11, 2021
Details:
Eligo will receive an upfront payment and R&D funding to advance EB005, until preclinical proof of concept. If GSK exercises its option, GSK and Eligo will enter into a license and collaboration agreement to jointly continue the development of EB005 in acne.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Undisclosed
Partner/Sponsor/Collaborator: University of Dundee
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 08, 2020
Details:
The collaboration aim to develop a novel class of medicines that target and degrade disease-causing proteins. The novel mechanism of action of PROTACs generates the possibility to eliminate disease relevant targets that were difficult to tackle with conventional approaches.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
Country
